GENETIC AORTIC DISORDERS ASSOCIATION CANADA
This organization has already been registered
Someone in your organization has already registered and setup an account. would you like to join their team?Profile owner : i**o@g********a.ca
Mission Statement
GADA Canada, through education, awareness, support and research is dedicated to saving lives and enabling a promising future for individuals living with any hereditary genetic aortic disorder, including the Marfan syndrome.
About This Cause
GADA Canada, previously known as The Canadian Marfan Association (CMA), was established in 1986 when very little was known about the genetic aortic disorder, Marfan syndrome (MFS). Since 2000, a multitude of genetic aortic disorders (GAD) have been identified, all of which are associated with different gene mutations. In light of this, with the agreement of the Canadian Marfan Association (CMA) Professional Advisory Board (PAB) in 2012, the Canadian Marfan Association (CMA) expanded its scope to support individuals diagnosed with all genetic aortic disorders (GAD). Since then, extensive work has been undertaken to transform the Canadian Marfan Association (CMA) into the Genetic Aortic Disorders Association Canada (GADA), which officially launched on September 26, 2015. In addition to providing support to an ever-growing community of those affected by hereditary thoracic aortic disease (HTAD) or genetic aortic disorders (GAD) caused by more than two-dozen different genetic mutations, GADA focuses on three key programs: i) Fostering aortic clinic formation throughout Canada to enhance patient access to multidisciplinary care for genetic aortic disorders (GAD) ii) The Montalcino Aortic Consortium (MAC), which GADA co-founded to address increased mortality among North American genetic aortic disorders (GAD) patients when compared to their European counterparts. Whereas North American patients were being treated according to Marfan syndrome (MFS) guidelines, European physicians were adapting them to specific patients. Montalcino Aortic Consortium (MAC) supports registry-based research to generate optimal diagnostic and therapeutic guidelines for each genetic aortic disorder (GAD) to extend life-expectancy globally. iii) Research Program With our achievements to date GADA, Montalcino Aortic Consortium (MAC) and the Temerty Foundation are recognized worldwide as leaders in building knowledge and supporting patients with all genetic aortic disorders (GAD). https://youtu.be/awJNxygIyPk